SOURCE: Entest BioMedical Inc.

February 17, 2010 08:10 ET

Entest BioMedical Publishes Journal Article on Laser Activation of Stem Cells for Treatment of Chronic Obstructive Pulmonary Disease (COPD)

Details of Regenerative Photoceutical Approach Disclosed in Peer-Reviewed Paper

SAN DIEGO, CA--(Marketwire - February 17, 2010) - Entest BioMedical Inc. (OTCBB: ENTB) announced publication of its manuscript "Lasers, Stem Cells, and COPD" in the peer-reviewed Journal of Translational Medicine. The manuscript was a collaborative effort led by Entest that included researchers from the University of California San Diego, University of Utah, the Center for the Study of Natural Oncology, and Cromos Pharma Services. The paper may be freely accessed at: http://www.translational-medicine.com/.

"Entest's Regenerative Photoceutical approach as represented by our ENT-576™ program offers the possibility of using laser light to direct stem cell homing and activation. To our knowledge this is the first description in the peer reviewed arena of treating COPD via this method," according to Dr. Feng Lin, principal investigator for Entest's COPD research.

Low level lasers have been utilized in medicine for decades with some being sold commercially in the United States under 510k exemption. Entest has identified applications for these low level lasers in potentially treating COPD in conjunction with stem cell therapy. Additionally, the Company has filed patent applications covering specific methods of using these devices to activate stem cells. Entest's proprietary ENT-576™ program utilizes localized laser therapy along with the administration of a drug that mobilizes patient stem cells in the treatment of COPD.

David Koos, Chairman & CEO of Entest, stated, "COPD is the 4th largest cause of death in the United States and it is Entest's deep desire to make an impact on finding a cure for this condition. By openly communicating our developmental ideas in a scientific format we hope to stimulate and engage others to work with us on solving this terrible problem."

About Entest BioMedical Inc.:

Entest BioMedical Inc. (OTCBB: ENTB) is involved with the development of stem cell therapy treatments for Chronic Obstructive Pulmonary Disease (COPD), immuno-cancer therapies, testing procedures for diabetes, stem cell research applications for diabetes and other illnesses. The Company also is involved with medical device development (including stem cell extraction instrumentation). ENT-576™ is a proprietary laser device currently under development by Entest. The Company has filed 3 patent applications relating to the treatment of COPD. Entest Biomedical, Inc. is a majority owned subsidiary of Bio-Matrix Scientific Group Inc. (OTCBB: BMSN).

About Bio-Matrix Scientific Group:

Bio-Matrix Scientific Group Inc. (OTCBB: BMSN) is a biotechnology company headquartered in San Diego, Ca. with a 15,000 sq. ft. facility that houses two secure cryogenic stem cell banks, three research laboratories, aseptic cellular/tissue class 10,000/100 processing lab, hematology, microbiology and flow cytometry laboratories. David Koos serves as Chairman & CEO concurrently for BMSN and ENTB.

Follow the Company's progress on Twitter:

http://twitter.com/Entest_BioMed

Disclaimer

This news release may contain forward-looking statements. Forward-looking statements are inherently subject to risks and uncertainties, some of which cannot be predicted or quantified. Future events and actual results could differ materially from those set forth in, contemplated by, or underlying the forward-looking statements. The risks and uncertainties to which forward-looking statements are subject include, but are not limited to, the effect of government regulation, competition and other material risks.

Contact Information